Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Pharmacy Times Continuing Education™.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-21-431-H01-P. The activity is available for CE credit through December 23, 2022.

This CE activity is also offered free online at www.pharmacytimes.org/per-postgame where you will be directed to the activity in its entirety, including the online pretest and posttest, activity evaluation, and request for credit.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

PER Postgame™: Protecting Patients with MS from COVID-19—Exploring the Latest in Prevention and Immunosuppressive Treatment Strategies

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

The COVID-19 pandemic is an unprecedented health care crisis with disproportionate impact on immunocompromised populations. There are unanswered questions and a lack of understanding about the immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) treated with disease modifying therapies (DMTs). With a continually changing therapeutic landscape based on emerging evidence, clinicians managing patients with MS require timely education on balancing SARS-CoV-2 infection risk with optimal disease control. This program sheds more light on cell-mediated responses to vaccines, how SARS-CoV-2 vaccines work, and current evidence surrounding DMTs for MS and vaccine response.

The PER Postgame™ is an innovative and unique webcast by PER®. It is an in-depth, engaging data recap program, focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward community neurologists, neuroimmunologists, MS specialists, specialty nurse practitioners, physician assistants, registered nurses, pharmacists, and other members of the MS care team.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the immunological pathways activated by vaccine administration
Explain the mechanisms underlying the antiviral efficacy of current SARSCoV-2 vaccines
Discuss the impact of disease-modifying therapies (DMTs) on anti-SARS-CoV-2 vaccine response in patients with MS
Implement timely, evidence-based strategies for addressing COVID-19 in patients with MS

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Chair

Matthew A. Tremblay, MD, PhD
Director of Multiple Sclerosis Research
Multiple Sclerosis Comprehensive Care Center
Department of Medicine
RWJ Barnabas Health
Livingston, New Jersey

Disclosures: Grant research support: Biogen; Consultant: Genentech; Speaker’s Bureau: Genentech.

Faculty

Aimee M. Banks, PharmD, BCPS, MSCS
Clinical Pharmacist, Multiple Sclerosis
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures: Advisory Board Consultant: Bristol Myers Squibb, EMD Serono, TG Therapeutics.

Joseph J. Sabatino, Jr., MD, PhD
Assistant Adjunct Professor Department of Neurology
University of California San Francisco
San Francisco, California

Disclosures: Grant research support: Novartis Pharmaceuticals.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.